Original short-acting GLP-1 agonist — twice-daily dosing.
Typical dose range: 5–10 mcg
Frequency: Twice daily
Route: Subcutaneous
Half-life: ~2.4 hours
Evidence level: Strong (FDA-approved)
Marketed as Byetta. Largely superseded by weekly GLP-1s, but still used clinically. Once-weekly extended-release version exists as Bydureon.